Market Research Industry Reports

Jazz Pharmaceuticals Plc (JAZZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem, sodium oxybate oral solution, for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze, an asparagine specific enzyme, for acute lymphoblastic leukemia; Prialt, ziconotide, for severe chronic pain in patients who are intolerant or refractory to other treatments and FazaClo orally disintegrating clozapine tablets indicated for the treatment of resistant schizophrenia. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals Plc (JAZZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.




Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 16
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million 18
Venture Financing 19
Arrivo BioVentures Raises USD49 Million in Venture Financing 19
Alize Pharma Raises USD1.9 Million in Venture Financing 20
Alize Pharma Raises USD6.4 Million in Series A Financing 21
Celator Pharma Raises US$39 Million In Venture Financing 22
Alize Pharma Raises US$4 Million In Venture Financing 23
Partnerships 24
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 24
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 25
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 26
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 27
Merger 28
Jazz Pharma Merges With Azur Pharma In All Stock Transaction 28
Licensing Agreements 30
Jazz Pharma Enters into License Agreement with XL-protein 30
Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 31
Jazz Pharma Amends Licensing Agreement with Pfenex 32
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 34
Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 36
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 37
Equity Offering 38
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 38
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 40
Debt Offering 42
Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 42
Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 43
Asset Transactions 44
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 44
Aytu BioScience Acquires ProstaScint from Jazz Pharma 45
Essex Bidco Acquires Assets from Jazz Pharma 46
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 48
Meda Completes Acquisition Of Womens Health Business From Jazz Pharma For US$95 Million 49
Acquisition 51
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 51
Jazz Pharma Acquires Alize Pharma 53
AstraZeneca May Acquire Ariad Pharma 54
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million 56
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 58
Jazz Pharmaceuticals Plc - Key Competitors 61
Jazz Pharmaceuticals Plc - Key Employees 62
Jazz Pharmaceuticals Plc - Locations And Subsidiaries 63
Head Office 63
Other Locations & Subsidiaries 63
Recent Developments 65
Financial Announcements 65
Feb 27, 2018: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results 65
Nov 07, 2017: Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results 67
Aug 08, 2017: Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results 68
May 09, 2017: Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results 69
Feb 28, 2017: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results 71
Corporate Communications 73
Dec 04, 2017: Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer 73
Clinical Trials 74
Jan 17, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75

List Of Tables

List of Tables
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Jazz Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 16
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million 18
Arrivo BioVentures Raises USD49 Million in Venture Financing 19
Alize Pharma Raises USD1.9 Million in Venture Financing 20
Alize Pharma Raises USD6.4 Million in Series A Financing 21
Celator Pharma Raises US$39 Million In Venture Financing 22
Alize Pharma Raises US$4 Million In Venture Financing 23
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 24
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 25
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 26
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 27
Jazz Pharma Merges With Azur Pharma In All Stock Transaction 28
Jazz Pharma Enters into License Agreement with XL-protein 30
Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 31
Jazz Pharma Amends Licensing Agreement with Pfenex 32
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 34
Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 36
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 37
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 38
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 40
Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 42
Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 43
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 44
Aytu BioScience Acquires ProstaScint from Jazz Pharma 45
Essex Bidco Acquires Assets from Jazz Pharma 46
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 48
Meda Completes Acquisition Of Womens Health Business From Jazz Pharma For US$95 Million 49
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 51
Jazz Pharma Acquires Alize Pharma 53
AstraZeneca May Acquire Ariad Pharma 54
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million 56
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 58
Jazz Pharmaceuticals Plc, Key Competitors 61
Jazz Pharmaceuticals Plc, Key Employees 62
Jazz Pharmaceuticals Plc, Other Locations 63
Jazz Pharmaceuticals Plc, Subsidiaries 63

List Of Figures

List of Figures
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12

Jazz Pharmaceuticals Plc (JAZZ) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem,

USD 250View Report

Jazz Pharmaceuticals plc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Jazz Pharmaceuticals plc Company Profile is a detailed strategic and analytical report on Jazz Pharmaceuticals plc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

Jazz Pharmaceuticals Plc (JAZZ) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem,

USD 250View Report

Hikma Pharmaceuticals PLC - Mergers and Acquisitions (M&A), Partnerships and Alliances and Investment Report

Hikma Pharmaceuticals PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Hikma Pharmaceuticals PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,

USD 350View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :75
Country :Ireland
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube